54gene
- Company typePrivate
- Founded2019
- HeadquartersWashington, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What 54gene does
54gene was a Nigerian health technology company founded in 2019 by Abasi Ene-Obong, focused on collecting, storing, and analyzing genetic data and biospecimens from African populations. The company addressed a documented gap in global genomic research, where African populations were historically underrepresented in genetic databases used for drug discovery and precision medicine. Its core offering centered on building a proprietary African genomic database through partnerships with healthcare and research institutions across the continent, with the intent to license this data and provide analysis services to pharmaceutical and biotech companies engaged in drug discovery and diagnostics development.
The company's go-to-market was direct enterprise sales targeting pharmaceutical companies, biotech firms, and research institutions, supported by participation in genomics industry conferences and scientific publications to build thought leadership. Its revenue model was data monetization — generating income through genomic data analysis services, biobanking functions, and licensing genetic data assets for pharmaceutical research. Customer segments were organized vertically: pharmaceutical and biotech companies seeking diverse genomic inputs for drug development, and healthcare and research institutions requiring African genomic data for disease diagnosis and treatment.
Despite raising over $45 million in total disclosed funding across seed (Y Combinator, 2019), Series A ($15M led by Adjuvant Capital, 2020), and Series B ($25M led by Cathay AfricInvest Innovation Fund, September 2021), 54gene collapsed after rapid COVID-era scaling and overextension. The company failed to convert post-seed momentum into sustainable revenue growth, and its founder subsequently transitioned to lead Syndicate Bio. The case is now cited as a cautionary example of African health-tech startups that achieved headline funding but could not reach commercial viability.
54gene firmographics
Firmographics- Name
- 54gene
- Legal name
- 54gene
- Website
- https://54gene.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
54gene industry classification
Industry- Product category
- Genomic Data Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Population Genomics & Preventive Precision Health Programs (HLAAANAL)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where 54gene is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
54gene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Genomic Data Services: Revenue generated through genomic data analysis services, biobanking functions, and potentially licensing genetic data for pharmaceutical research and drug discovery purposes
Distribution channels1 record
Marketing channels2 records
54gene product offering
Product offeringCore offering
54gene was a health technology company that collected, stored, and analyzed genetic data and biospecimens from African populations to improve genomic diversity in research, diagnosis, and disease treatment. The company provided genomic data services, biobanking functions, and analytical capabilities to pharmaceutical, biotech, and research institutions for drug discovery and diagnostics development.
Product overview
54gene was a health technology company focused on African genomics, working to improve genomic diversity in research, diagnosis, and treatment of diseases. The company was involved in drug discovery, genomics, and diagnostics across Africa. However, specific named products or modules are not detailed in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- African Genomic Data Collection and Analysis
Companies that use 54gene
Customer profileSegments2 records
Ideal customer profiles2 records
54gene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
54gene partnerships and signals
Strategic signalScale indicators3 records
Recent moves2 records
Expansion highlights4 records
54gene competitors and assessment
Company assessmentDirect peers
- 23andMe: Consumer and therapeutics genomics company that built a large proprietary genetic database and licenses data to pharmaceutical companies for drug discovery. Closely comparable to 54gene's genomic-data-plus-pharma-partnership model.
- Helix: Population genomics and DNA sequencing platform that partners with health systems and population-health programs to build large-scale genomic databases. Directly comparable business model to 54gene's biobank-plus-pharma approach.
- Color Health: Population genomics company offering genetic testing at scale and partnering with employers, health systems, and pharma on population health. Directly comparable genomics-as-a-service proposition with enterprise B2B channels similar to 54gene's pharma and research customers.
Broad incumbents
- Ancestry: Operates one of the world's largest consumer genomic databases with extensive ancestry-focused DNA collections and ancillary health services. Comparable as a large-scale genomic data operator, though skewed toward European-ancestry samples unlike 54gene's African focus.
- deCODE genetics: Iceland-based genomics pioneer now owned by Amgen that built a national-scale population biobank used for drug target discovery. Highly comparable as a population-genomics-for-drug-discovery business, though at greater scale and maturity.
Others
- Regeneron Genetics Center: Pharma-sponsored large-scale human sequencing effort linked to drug discovery at Regeneron. Comparable as a model where a biobank is tied directly into pharma pipelines, though embedded within a single sponsor rather than sold across the industry like 54gene.
Emerging players
- Human Longevity Inc. Genomics and precision-health company combining large-scale sequencing with health-risk prediction and pharma partnerships. Comparable technology stack and go-to-market, though focused on wealthy individual customers rather than African populations.
- Nebula Genomics: Personal genomics platform that emphasizes privacy-preserving genomic data ownership and serves both consumers and researchers. Comparable data-monetization model where individuals contribute genetic data that is licensed for research.
- Syndicate Bio: African-focused genomics venture founded by 54gene's former founder, Abasi Ene-Obong, after 54gene's collapse. Most directly comparable as a continuation of the African genomic data thesis using the same domain expertise.
Regional players
- Genomics England: UK government-backed initiative building a national genomic dataset from the NHS for research and clinical use. Comparable as a population-scale genomics platform; operates under a public mandate in a single country rather than across African markets.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
54gene social profiles
Digital presence54gene financial estimates
Financial estimateRevenue estimate
Valuation estimate
54gene leadership team
Management profileNumber of profiles
54gene funding detail
Funding detailFunding overview
Funding rounds8 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
54gene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 54gene
What does 54gene do?
54gene was a health technology company that collected, stored, and analyzed genetic data and biospecimens from African populations to improve genomic diversity in research, diagnosis, and disease treatment. The company provided genomic data services, biobanking functions, and analytical capabilities to pharmaceutical, biotech, and research institutions for drug discovery and diagnostics development.
Is 54gene a public or private company?
54gene is a private company. It is classified as venture growth investor backed and is currently closed.
When was 54gene founded?
54gene was founded in 2019. It employs 11 to 50 people.
Where is 54gene based?
54gene is headquartered in Washington, United States, in the North America region.
How does 54gene make money?
One revenue line is on record: genomic Data Services.
Who are 54gene's main competitors?
Direct peers on record are 23andMe, Helix and Color Health. Broad incumbents are Ancestry and deCODE genetics. Regeneron Genetics Center is listed as an others. Emerging players are Human Longevity Inc., Nebula Genomics and Syndicate Bio. Genomics England is listed as a regional player.
Does 54gene have an API?
No public API is recorded for 54gene.
What industry is 54gene in?
54gene's product category is Genomic Data Services. Its primary akta.pro industry code is HLAAANAL, Population Genomics & Preventive Precision Health Programs, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.